Increased myocardial expression of phosphodiesterase 5 impairs functional recovery in experimental cardiomyopathy and is associated with end-stage clinical heart failure
Péter Pokreisz(Ghent University), Stefan Janssens(Maastricht University), Sara Vandenwijngaert(Massachusetts General Hospital), Bitó, Paul Herijgers(KU Leuven), Karin R. Sipido(KU Leuven), Glenn Marsboom(Johnson & Johnson (United States)), KD Bloch, Johan Vanhaecke(Apple (Israel)), An Van den Bergh(Vlaams Instituut voor Biotechnologie)
Unknown
January 1, 2008
Cited by 0
Related Papers
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Rosuvastatin in Older Patients with Systolic Heart Failure
|New England Journal of Medicine|2007|1.5k
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889
Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer
|The FASEB Journal|2012|606